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Objective: To establish a resistance (R) surveillance program monitoring antimicrobial sus-
ceptibility  patterns in Latin America (LATAM; Argentina [ARG], Brazil [BRA], Chile, Colombia
[CBA],  Costa Rica, Ecuador [ECU], Guatemala [GUA], Mexico [MEX], Panama [PAN], Peru, and
Venezuela [VEN]).
Methods:  In 2011, 4979 organisms were collected from 11 nations (20 laboratories) for suscep-
tibility  testing in a central laboratory design. Antimicrobials were  tested by CLSI methods
and  results interpreted by CLSI and EUCAST breakpoints. Most common Gram-positive
(Staphylococcus aureus [SA, 921], other staphylococci [CoNS; 299], enterococci [218], Strepto-
coccus  pneumoniae [SPN; 182], -haemolytic streptococci [115]) and Gram-negative (E. coli [EC;
644], Klebsiella spp. [KSP; 517], Enterobacters [272], Pseudomonas aeruginosa [PSA; 586], Acine-
tobacters  [ACB; 494]) pathogens were analyzed against linezolid (LZD), vancomycin (VAN),
tigecycline  (TIG), colistin (COL), cefoperazone/sulbactam (C/S), and amikacin (AMK).
Results: MRSA rates varied from 29% (CBA, BRA) to 79% (Peru); but LZD (MIC90, 2 mg/L), TIG
(MIC90, 0.12 mg/L) and VAN (MIC90, 1 mg/L) covered all strains. Enterococci showed a 14%VRE  rate, highest in BRA and MEX; all inhibited by TIG and daptomycin, but not LZD (three
non-susceptible  with G2576T mutations or cfr). Penicillin-R among SPN and viridans strep-
tococci  was 51.6 and 41.1%, respectively. LZD overall R against Gram-positives was 0.3%.
e observed in EC (54–71%) and KSP (≥50%) from GUA, MEX and Peru,High  ESBL rates wer
and  six nations, respectively. Carbapenem-R in KSP was 9%, highest rates associated with
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KPC in BRA, CBA, ECU, PAN and VEN; also a NDM-1 in KSP from CBA. AMK, TIG, C/S and
carbapenems were the broadest-spectrum agents tested against Enterobacteriaceae. Only
COL inhibited >90% of PSA; COL and TIG (≤2 mg/L) covered ≥85% of ACB.
Conclusions: LATAM nations demonstrated variable levels of antimicrobial R especially
among Enterobacteriaceae (-lactamase-mediated), PSA and ACB. MRSA (48%), VRE (14%)
and multidrug-R SPN were also regional therapeutic challenges.
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13 Entroduction
ecent escalations of -lactamase-mediated resistances
extended-spectrum -lactams [ESBL], serine carbape-
amases [KPCs], OXA-series Class D enzymes, and
etallo--lactamases [MBL]) worldwide has complicated
ntimicrobial therapy of important/common Gram-negative
acillary infections.1–4 Already existing resistance chal-
enges  among Gram-positive cocci (methicillin-resistant
taphylococci, vancomycin-resistant enterococci [VRE]
nd  multidrug-resistant [MDR] pneumococci) further
mphasize the needs for global, regional, national and
ocal  surveillance of antimicrobial susceptibility pat-
erns  to guide empiric therapy and direct or monitor
nterventions.5–7 These resistant strains increase patient
orbidity and mortality, as well as the cost of medical care
elivery.4,7
Current surveillance programs, particularly at the global
evel,1–3 have concentrated on larger economically developed
ations where ﬁscal markets and supporting regulatory agen-
ies  (USA-FDA, EMA) would recognize the value, and have
he  resources to sustain monitoring. In contrast, surveil-
ance  data from countries outside the major markets having
aced  more  limited support for drug resistance monitoring,
rug  patent protection, prescription drug law and antimi-
robial  stewardship programs  are more  limited.4 Beginning
n  2011, the Latin American (LATAM) surveillance programs
SENTRY Antimicrobial Surveillance Program and several oth-
rs)  administered by JMI  Laboratories (North Liberty, Iowa,
SA)  were  expanded to include sites within some countries
aving  limited sampling support or not having signiﬁcant
eported statistics. This regional resistance surveillance pro-
ram  provides reference susceptibility test information in
everal  areas of the world including 11 countries in LATAM
ncluding seven that are uncommonly sampled (Colombia,
osta  Rica, Ecuador, Guatemala, Panama, Peru and Venezuela).
ata  from testing nearly 5000 clinical isolates in 2011 are pre-
ented  here.
aterials  and  methods
ations  and  organisms  sampled
leven countries in LATAM (20 laboratory sampling sites hav-
ng  93–503 organism samples/site) were sampled with a target
© 20f  ≥250 isolates per nation. These institutions were gener-
lly  tertiary-care hospitals. The compliance to protocol ranged
rom  190 [Venezuela, 95%] to >100% for the “developed” coun-
ries.  The collected organisms were isolated consecutivelyfrom various types of clinical infections (prevalence design)
including  bloodstream (18.8%), respiratory tract (20.1%), skin
and  skin structure (13.1%) as well as other or unspeciﬁed body
sites.  The countries (sites; sample size) were:  Argentina (two;
498),  Brazil (ﬁve; 1588), Chile (two; 467), Colombia (one; 208),
Costa  Rica (one; 193), Ecuador (one; 192), Guatemala (one; 201),
Mexico  (three, 1052), Panama (one; 196), Peru (one; 194) and
Venezuela  (two, 190); one isolate per patient per infectious
episode, see Table 1. The organisms forwarded to the moni-
toring  central laboratory (JMI Laboratories) were  as follows: S.
aureus (921), coagulase-negative Staphylococcus species (CoNS;
299),  enterococci (218; 92.2% E. faecalis or E. faecium), S. pneumo-
niae  (182), -haemolytic streptococci (115; 92.2% S. pyogenes or
S. agalactiae), viridans group streptococci (90; more  than eight
species),  E. coli (644; 37.3% ESBL phenotype), Klebsiella spp.
(517;  three species, 52.4% ESBL phenotype), Enterobacter spp.
(272),  P. mirabilis (74; 24.3% ESBL phenotype), other Enterobac-
teriaceae (292), H. inﬂuenzae (128; 29.7% -lactamase-positive),
M. catarrhalis (33), P. aeruginosa (586), and Acinetobacter spp.
(494;  94.7% A. baumannii). A total of 4979 isolates were  tested,
4865  or 97.7% of which are presented in Tables 2 and 3; the
remaining  organisms occurred in small numbers precluding
a  signiﬁcant sample size per species, e.g. limited analytical
power.
Organisms detected with resistances to key, available
agents were tested by various molecular methods such as PCR
ampliﬁcation/sequencing, example ESBLs, MBLs, MDR  Gram-
negative  bacilli or Gram-positive cocci.1,2
Methods  and  antimicrobials  tested
CLSI M07-A9 (2012) methods were applied using validated
broth  microdilution panels produced by ThermoFisher Scien-
tiﬁc  Inc., formerly TREK Diagnostics (Cleveland, Ohio, USA).8
Interpretations of results utilized CLSI (M100-S23, 2013), USA-
Food  and Drug Administration (FDA) and EUCAST (2013)
criteria;9–11 and the results of quality control (QC) tests were
dominantly (nearly 99.0%) within QC ranges (CLSI M100-S23)
for  six utilized control organisms.
The sponsor’s (Pﬁzer Inc., New York, New York,
USA) compounds included: linezolid, tigecycline,
piperacillin/tazobactam, ampicillin/sulbactam, cefoperazone
and  cefoperazone/sulbactam. For studying Gram-negative
bacilli, Gram-positive cocci, and fastidious respiratory tract
species,  numerous additional (15–25) drugs were  also tested.
ESBL  patterns were  deﬁned for E. coli, Klebsiella spp. and
lsevier Editora Ltda.Este é um artigo Open Access sob a licença de CC BY-NC-NDProteus  mirabilis per CLSI (2013) criteria as a MIC  of ≥2 mg/L
for  aztreonam or ceftriaxone or ceftazidime.9,10 Carbapenem-
resistant Enterobacteriaceae (CRE) were detected by a MIC  at
≥2 mg/L for doripenem or imipenem or meropenem.9
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Table 1 – Summary of important emerging resistance proﬁles detected in 11 Latin American countries (20 medical
centers; 2011); a 4979 isolate sample.
Nation (no. sites/strains) ESBL (%)a CARB–R(%)a VRE (%)a MRSA (%)a
EC KSP KSP COL and TIG-S Rate VanA Rate LZD -S
Argentina (two/498) 20 53 11–12 96 to 98 10 100 55 100
Brazil (ﬁve/1588) 18 50 17–18 93  to 99 27 89 29 100
Chile (two/467) 28 59 0 – 0 – 68 100
Colombia (one/208) 24 41 9–18 96 to 100 11 31 29 100
Costa Rica (one/193) 7 19 0 – 7 100 55 100
Ecuador (one/192) 20 40 5 100 0 – 31 100
Guatemala (one/201) 59 69 0 – 9 100 49 100
Mexico (three/1052) 71 56 0 – 26 100 48 100
Panama (one/196) 37 40 20 100 13 100 47 100
Peru (one/194) 54 70 0 – 16 100 79 100
Venezuela (two/190) 10 40 15 90 to 100 12 67 63 100
All (20/4979) 37 52 9 97 14 91 48 100
a EC, E. coli; KSP, Klebsiella spp.; TIG, tigecycline; COL, colistin; CARB-R, carbapenem-resistant; VRE, vancomycin-resistant enterococci, MRSA,
eptibmethicillin-resistant S. aureus; LZD-S, linezolid-susceptible; S, susc
Results  and  discussion
Antimicrobial  proﬁles  of  1825  Gram-positive  pathogens
(Tables  1  and  2)
S. aureus isolates (921, 47.8% MRSA overall) exhibited
complete (100.0%) susceptibility to linezolid (MIC50/90,
1/2  mg/L), daptomycin (MIC50/90, 0.25/0.5 mg/L), tigecycline
(MIC50/90, 0.06/0.12 mg/L) and vancomycin (MIC50/90, 1/1 mg/L).
Rare  (1.1%) resistance to trimethoprim/sulfamethoxazole
(TMP/SMX) was  observed (Table 2). Aminoglycoside (gentam-
icin)  resistance was  approximately 20.0% with higher rates
documented in Peru (72.2%), Chile (30.0%), Argentina (30.7%)
and  Venezuela (30.6%).
CoNS  samples (299; 83.9% methicillin-resistant) showed
common co-resistances and only four agents with >90% sus-
ceptibility  rates including linezolid, daptomycin, doxycycline,
and  vancomycin (94.3–100.0% susceptible). The rare occur-
rences  of linezolid non-susceptibility (1.7%) occurred in Brazil
(ﬁve  strains [4.8%]; three species [S. epidermidis, three clonal
isolates  with a G2576 mutation; one S. hominis with a G2576, L3
at  F1475 and M156 T, and L4 at 577 T mutations and one S. lug-
dunensis  with a G2576 mutation]) with MIC  values of 8–32 mg/L;
and  Mexico (two strains of S. epidermidis and S. haemolyti-
cus  having cfr ± L3 or L4 mutations) with MIC values at only
4  mg/L. Teicoplanin non-susceptible results (11.4% by EUCAST
breakpoints)  were  found in Brazil (10 strains, 9.6%), Costa Rica
(six  strains, 42.9%), Mexico (eight strains, 8.9%), Panama (two
strains,  15.4%), Peru (two strains, 14.3%), and Venezuela (ﬁve
strains,  45.5%).
Enterococci (218, either E. faecalis or E. faecium) had a
VRE  rate of 14.2–15.1% and 91.4–93.7% with a VAN-A pattern
(Tables  1 and 2). Ten nations had documented VRE (range,
7.1%  [Costa Rica] to 25.7–26.5% [Brazil and Mexico]), and the
best  tested agents (% susceptible) were  linezolid (98.6%), dap-
tomycin  (100.0%), teicoplanin (86.2–86.7%) and vancomycin
(84.9%). Linezolid non-susceptibility was  detected in Brazil
(2.9%  prevalence overall; G2576 mutations in a clonalle.
E.  faecalis) and in Panama City, Panama (13.3% prevalence; cfr
clonal  occurrences in E. faecalis).
S. pneumoniae (182) isolates from LATAM were  dominantly
penicillin-non-susceptible (51.6%; using CLSI non-meningitis
breakpoints) with highest rates observed in Mexico (84.8%) and
Venezuela  (81.2%). Similarly, ceftriaxone non-susceptible rates
were elevated (21.1–43.7%) in the same two nations. Poor cov-
erage  (low susceptible %) were noted for erythromycin (62.6%),
tetracycline  (63.7–64.8%) and TMP/SMX (45.1–48.4%). The best
antimicrobials tested against pneumococci were  levoﬂoxacin,
linezolid, tigecycline and vancomycin, each inhibiting all
strains  at published breakpoints (Table 2). For other strep-
tococci,  important resistance proﬁles observed were:  (1) 13.9
and  56.5% non-susceptible for macrolides and tetracyclines in
-haemolytic streptococci, respectively, (2) ≥91.1% suscepti-
ble  rates for all drugs except penicillin (58.9%, CLSI criteria),
erythromycin (50.0%) and tetracycline (61.1%) in viridans
group  streptococci, and (3) rare daptomycin (1.1%) and ﬂuo-
roquinolone non-susceptible (1.7–3.3%) rates were  observed
(Table  2).
Antimicrobial  proﬁles  of  Gram-negative  bacilli  are  found
in Tables  3  and  4
E. coli (644) had an ESBL-phenotype rate of 37.3%, see Table 4.
The  most active tested agents were amikacin (92.7% suscep-
tible),  cefoperazone/sulbactam (92.7%), meropenem (100.0%)
and  tigecycline (100.0%). The most active cephalosporin
against E. coli was  cefepime at 72.4% by CLSI breakpoints
(Table 3). Klebsiella spp. (517) showed very elevated resis-
tance  rates (Table 3), with only four drugs inhibiting ≥80.0%
of  isolates (tigecycline [97.9%], colistin [96.5%], meropenem
[90.3%] and amikacin [89.0%]). The ESBL phenotype rate was
52.4%  (Table 4), and CRE were identiﬁed (no./percentage) in
Argentina  (6/10.7), Brazil (31/17.3), Colombia (4/18.2), Ecuador
(2/10.0),  Mexico (1/1.1), Panama (4/20.0) and Venezuela (3/15.0).
The  following carbapenemases were identiﬁed: KPC-2 (Brazil,3
Ecuador,2 Venezuela3), KPC-3 (Colombia,2 Panama3) and NDM-
1  (Colombia1). P. mirabilis (74) showed an ESBL-phenotype rate
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Table 2 – Activity of selected antimicrobial agents when tested against 1825 Gram-positive pathogens from Latin America
nations (2011).
Organism (no. tested)/antimicrobial agents MIC (mg/L) CLSIa %S/%R EUCASTa %S/%R
50% 90% Range
S. aureus (921)
Linezolid 1 2 0.25 to 2 100.0/0.0 100.0/0.0
Tigecyclineb 0.06 0.12 ≤0.03 to 0.25 100.0/− 100.0/0.0
Piperacillin/tazobactam 2 >64 ≤0.5 to >64 52.2/47.8 52.2/47.8
Amoxicillin/clavulanate ≤1 >8 ≤1 to >8 52.2/47.8 52.2/47.8
Ceftriaxone 4 >8 1 to >8 52.2/47.8 52.2/47.8
Clindamycin ≤0.25 >2 ≤0.25 to >2 65.4/34.6 65.0/34.6
Daptomycin 0.25 0.5 0.12 to 1 100.0/− 100.0/0.0
Doxycycline 0.12 0.5 ≤0.06 to 8 98.6/0.0 95.7/2.1
Erythromycin 0.5 >16 ≤0.12 to >16 51.6/46.9 52.0/47.4
Gentamicin ≤1 >8 ≤1 to >8 80.5/18.9 79.9/20.1
Levoﬂoxacin 0.25 >4 ≤0.12 to >4 63.1/36.3 63.1/36.3
Meropenem 0.12 >8 ≤0.06 to >8 52.2/47.8 52.2/47.8
Oxacillin 1 >2 ≤0.25 to >2 52.2/47.8 52.2/47.8
Penicillin >8 >8 ≤0.06 to >8 7.5/92.5 7.5/92.5
Trimethoprim/sulfamethoxazole ≤0.5 ≤0.5 ≤0.5 to >4 98.4/1.6 98.4/1.3
Vancomycin 1 1 0.5 to 2 100.0/0.0 100.0/0.0
CoNS (299)c
Linezolid 0.5 1 0.25 to >8 98.3/1.7 98.3/1.7
Tigecyclineb 0.06 0.12 ≤0.03 to 0.5 −/− 100.0/0.0
Piperacillin/tazobactam 2 >64 ≤0.5 to >64 16.1/83.9 16.1/83.9
Amoxicillin/clavulanate 2 >8 ≤1 to >8 16.1/83.9 16.1/83.9
Ceftriaxone >8 >8 0.5 to >8 16.1/83.9 16.1/83.9
Clindamycin 0.5 >2 ≤0.25 to >2 50.2/48.5 48.5/49.8
Daptomycin 0.5 0.5 ≤0.06 to 1 100.0/− 100.0/0.0
Doxycycline 0.5 2 ≤0.06 to >8 94.3/2.0 87.6/8.7
Erythromycin >16 >16 ≤0.12 to >16 28.8/70.2 28.8/70.9
Gentamicin 8 >8 ≤1 to >8 41.8/45.5 35.8/64.2
Levoﬂoxacin 4 >4 ≤0.12 to >4 41.5/54.8 41.5/54.8
Meropenem 2 >8 ≤0.06 to >8 16.1/83.9 16.1/83.9
Oxacillin >2 >2 ≤0.25 to >2 16.1/83.9 16.1/83.9
Penicillin 8 >8 ≤0.06 to >8 9.0/91.0 9.0/91.0
Trimethoprim/sulfamethoxazole 2 >4 ≤0.5 to >4 50.2/49.8 50.2/27.1
Vancomycin 2 2 0.5 to 4 100.0/0.0 100.0/0.0
Enterococci (218)d
Linezolid 1 2 0.5 to 8 98.6/0.5 99.5/0.5
Tigecyclineb 0.06 0.06 ≤0.03 to 0.25 100.0/− 100.0/0.0
Piperacillin/tazobactam 8 >64 ≤0.5 to >64 75.2/− 75.2/−
Amoxicillin/clavulanate ≤1 >8 ≤1 to >8 75.2/− 75.2/24.8
Ampicillin 1 >8 ≤0.25 to >8 75.2/24.8 73.4/24.8
Daptomycin 1 2 ≤0.06 to 4 100.0/− −/−
Doxycycline 8 >8 ≤0.06 to >8 42.7/20.2 −/−
Erythromycin >16 >16 ≤0.12 to >16 10.1/66.1 −/−
Imipenem 1 >8 ≤0.12 to >8 −/− 73.4/25.2
Levoﬂoxacin 2 >4 0.5 to >4 54.6/40.8 −/−
Teicoplanin ≤2 >16 ≤2 to >16 86.7/13.3 86.2/13.8
Vancomycin 1 >16 0.25 to >16 84.9/14.2 84.9/15.1
S.pneumoniae
Penicillin-susceptible (88)
Linezolid  1 1 0.25 to 1 100.0/− 100.0/0.0
Tigecyclineb ≤0.03 0.06 ≤0.03 to 0.06 100.0/− −/−
Amoxicillin/clavulanate ≤1 ≤1 ≤1 to 4 98.9/0.0 −/−
Ceftriaxone ≤0.06 ≤0.06 ≤0.06 to 1 100.0/0.0 97.7/0.0
Clindamycin ≤0.25 ≤0.25 ≤0.25 100.0/0.0 100.0/0.0
Erythromycin ≤0.12 8 ≤0.12 to 16 87.5/12.5 87.5/12.5
Levoﬂoxacin 1 1 0.5 to >4 97.7/2.3 97.7/2.3
Meropenem ≤0.06 ≤0.06 ≤0.06 to 0.5 98.9/0.0 100.0/0.0
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Table 2 (Continued)
Organism (no. tested)/antimicrobial agents MIC (mg/L) CLSIa %S/%R EUCASTa %S/%R
50% 90% Range
Penicilline ≤0.06 ≤0.06 ≤0.06 100.0/0.0 −/−
Tetracycline 0.5 >8 ≤0.25 to >8 80.7/19.3 79.5/19.3
Trimethoprim/sulfamethoxazole ≤0.5 4 ≤0.5 to >4 75.0/17.0 81.8/17.0
Vancomycin 0.5 0.5 ≤0.12 to 0.5 100.0/− 100.0/0.0
Penicillin-intermediate (40)
Linezolid  1 1 0.5 to 1 100.0/− 100.0/0.0
Tigecyclineb ≤0.03 0.06 ≤0.03 to 0.06 100.0/− −/−
Amoxicillin/clavulanate ≤1 ≤1 ≤1 to 4 97.5/0.0 −/−
Ceftriaxone 0.25 0.5 ≤0.06 to 1 100.0/0.0 97.5/0.0
Clindamycin ≤0.25 >2 ≤0.25 to >2 75.0/25.0 75.0/25.0
Erythromycin ≤0.12 >16 ≤0.12 to >16 55.0/45.0 55.0/45.0
Levoﬂoxacin 1 1 0.5 to 1 100.0/0.0 100.0/0.0
Meropenem ≤0.06 0.25 ≤0.06 to 0.5 92.5/0.0 100.0/0.0
Penicilline 0.25 1 0.12 to 1 100.0/0.0 −/−
Tetracycline 0.5 >8 ≤0.25 to >8 72.5/25.0 70.0/27.5
Trimethoprim/sulfamethoxazole 2 >4 ≤0.5 to >4 35.0/40.0 35.0/40.0
Vancomycin 0.25 0.5 0.25 to 0.5 100.0/− 100.0/0.0
Penicillin-resistant (54)
Linezolid  0.5 1 0.5 to 1 100.0/− 100.0/0.0
Tigecyclineb ≤0.03 0.06 ≤0.03 to 0.06 100.0/− −/−
Amoxicillin/clavulanate 2 8 ≤1 to 8 50.0/31.5 −/−
Ceftriaxone 1 2 0.5 to >8 50.0/1.9 5.6/1.9
Clindamycin >2 >2 ≤0.25 to >2 42.6/55.6 44.4/55.6
Erythromycin >16 >16 ≤0.12 to >16 27.8/72.2 27.8/72.2
Levoﬂoxacin 1 1 0.5 to 1 100.0/0.0 100.0/0.0
Meropenem 0.5 1 0.25 to 1 5.6/40.7 100.0/0.0
Penicilline 4 4 2 to 4 40.7/0.0 −/−
Tetracycline >8 >8 ≤0.25 to >8 33.3/66.7 33.3/66.7
Trimethoprim/sulfamethoxazole >4 >4 ≤0.5 to >4 3.7/90.7 3.7/90.7
Vancomycin 0.25 0.5 0.25 to 1 100.0/− 100.0/0.0
-Haemolytic streptococci (115)f
Linezolid 1 1 0.5 to 1 100.0/− 100.0/0.0
Tigecyclineb ≤0.03 0.06 ≤0.03 to 0.12 100.0/− 100.0/0.0
Piperacillin/tazobactam ≤0.5 ≤0.5 ≤0.5 −/− 100.0/0.0
Amoxicillin/clavulanate ≤1 ≤1 ≤1 −/− 100.0/0.0
Ceftriaxone ≤0.06 0.12 ≤0.06 to 0.25 100.0/− 100.0/0.0
Clindamycin ≤0.25 ≤0.25 ≤0.25 to >2 92.2/7.8 92.2/7.8
Daptomycin 0.12 0.25 ≤0.06 to 0.5 100.0/− 100.0/0.0
Erythromycin ≤0.12 4 ≤0.12 to >16 86.1/13.9 86.1/13.9
Levoﬂoxacin 0.5 1 0.25 to >4 98.3/0.9 93.9/1.7
Meropenem ≤0.06 ≤0.06 ≤0.06 100.0/− −/−
Penicillin ≤0.06 ≤0.06 ≤0.06 to 0.12 100.0/− 100.0/0.0
Tetracycline >8 >8 ≤0.25 to >8 43.5/56.5 42.6/56.5
Trimethoprim/sulfamethoxazole ≤0.5 ≤0.5 ≤0.5 to >4 −/− 99.1/0.9
Vancomycin 0.5 0.5 0.25 to 1 100.0/− 100.0/0.0
Viridans gr. Streptococci (90)g
Linezolid 1 1 0.25 to 2 100.0/− −/−
Tigecyclineb ≤0.03 0.06 ≤0.03 to 0.25 100.0/− −/−
Ceftriaxone 0.25 1 ≤0.06 to 2 95.6/0.0 87.8/12.2
Clindamycin ≤0.25 ≤0.25 ≤0.25 to >2 91.1/7.8 92.2/7.8
Daptomycin 0.25 1 ≤0.06 to 2 98.9/− −/−
Erythromycin ≤0.12 4 ≤0.12 to >16 50.0/50.0 −/−
Levoﬂoxacin 1 2 0.25 to >4 96.7/2.2 −/−
Meropenem ≤0.06 0.25 ≤0.06 to 2 97.8/− 100.0/0.0
Penicillin 0.12 1 ≤0.06 to >8 58.9/3.3 82.2/3.3
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Table 2 (Continued)
Organism (no. tested)/antimicrobial agents MIC (mg/L) CLSIa %S/%R EUCASTa %S/%R
50% 90% Range
Tetracycline 0.5 >8 ≤0.25 to >8 61.1/34.4 −/−
Vancomycin 0.5 0.5 0.25 to 1 100.0/− 100.0/0.0
a Criteria as published by the CLSI and EUCAST9,10, -lactam susceptibility should be directed by the oxacillin test results.
b USA-FDA breakpoints were applied when available.11
c Includes: Staphylococcus auricularis (one strain), S. capitis (10 strains), S. epidermidis (118 strains), S. equorum (one strain), S. haemolyticus (48
strains), S. hominis (29 strains), S. lugdunensis (10 strains), S.saprophyticus (six strains), S. warneri (three strains), S. xylosus (three strains), and
unspeciated coagulase-negative staphylococci (70 strains).
d Includes: Enterococcus avium (11 strains), E. durans (one strain), E. faecalis (142 strains), E. faecium (59 strains), E. gallinarum (four strains), and E.
hirae (one strain).
e Criteria were those published by the CLSI9 for ‘Penicillin parenteral (non-meningitis)’, as were the ceftriaxone breakpoints.
f Includes: Streptococcus dysgalactiae (three strains), Group A Streptococcus (44 strains), Group B Streptococcus (62 strains), Group C Streptococcus
(one strain), Group F Streptococcus (one strain), and Group G Streptococcus (four strains).
g Includes: Streptococcus anginosus (ﬁve strains), S. bovis (one strain), S. gallolyticus (seven strains), S. infantarius (one strain), S. mitis (16 strains), S.
parasanguinis (one strain), S. salivarius (two strains), S. sanguinis (two strains), unspeciated Streptococcus (one strain), and unspeciated viridans
group streptococci (54 strains).
Table 3 – Activity of selected antimicrobial agents when tested against 3040 isolates of Gram-negative pathogens from
Latin American nations (2011).
Organism (no. tested)/antimicrobial agent MIC (mg/L) CLSIa %S/%R EUCASTa %S/%R
50% 90% Range
E. coli (644)
Ampicillin/sulbactam 16 >32 ≤0.25 to >32 30.4/49.1 30.4/69.6
Cefoperazone 4 >32 ≤0.25 to >32 59.6/38.2 −/−
Cefoperazone/sulbactamb 2 16 ≤0.25 to >32 92.7/2.3 −/−
Piperacillin/tazobactam 2 32 ≤0.5 to >64 86.5/5.0 78.7/13.5
Tigecyclinec 0.12 0.25 ≤0.03 to 1 100.0/0.0 100.0/0.0
Amikacin 4 8 0.5 to >32 97.5/0.8 92.4/2.5
Amoxicillin/clavulanate 8 >8 ≤1 to >8 58.4/41.6 58.4/41.6
Ampicillin >8 >8 1 to >8 23.3/76.7 23.3/76.7
Cefepime ≤0.5 >16 ≤0.5 to >16 72.4/23.9 64.8/30.4
Ceftazisdime 0.25 32 0.03 to >32 69.6/27.2 65.5/30.4
Ceftriaxone 0.12 >8 ≤0.06 to >8 62.9/37.1 62.9/37.1
Gentamicin ≤1 >8 ≤1 to >8 72.4/27.0 70.7/27.6
Levoﬂoxacin 4 >4 ≤0.12 to >4 49.7/47.2 49.4/50.3
Meropenem ≤0.06 ≤0.06 ≤0.06 to 0.5 100.0/0.0 100.0/0.0
Tetracycline >8 >8 ≤0.25 to >8 40.4/59.3 −/−
Tobramycin 1 >16 0.25 to >16 62.6/32.3 61.2/37.4
Trimethoprim/sulfamethoxazole >4 >4 ≤0.5 to >4 40.0/60.0 40.0/59.3
Klebsiella spp. (517)d
Ampicillin/sulbactam 32 >32 1 to >32 40.6/53.6 40.6/59.4
Cefoperazone >32 >32 ≤0.25 to >32 47.2/51.1 −/−
Cefoperazone/sulbactamd 4 >32 ≤0.25 to >32 71.8/21.5 −/−
Piperacillin/tazobactam 4 >64 ≤0.5 to >64 66.2/25.1 59.0/33.8
Tigecyclinec 0.25 1 ≤0.03 to >4 97.9/0.2 95.0/2.1
Amikacin 2 32 0.5 to >32 89.0/6.0 82.8/11.0
Amoxicillin/clavulanate 8 >8 ≤1 to >8 52.4/47.6 52.4/47.6
Cefepime 1 >16 ≤0.5 to >16 62.3/32.9 51.8/42.4
Ceftazidime 1 >32 ≤0.015 to >32 57.3/37.3 51.8/42.7
Ceftriaxone 8 >8 ≤0.06 to >8 48.7/51.1 48.7/51.1
Gentamicin ≤1 >8 ≤1 to >8 68.5/27.5 67.1/31.5
Levoﬂoxacin 0.25 >4 ≤0.12 to >4 68.7/30.0 67.1/31.3
Meropenem ≤0.06 1 ≤0.06 to >8 90.3/7.9 92.1/5.6
Tetracycline 2 >8 ≤0.25 to >8 62.3/35.2 −/−
Tobramycin 1 >16 ≤0.12 to 16 57.6/37.1 56.9/42.4
Trimethoprim/sulfamethoxazole ≤0.5 >4 ≤0.5 to >4 57.1/42.9 57.1/41.0
P. mirabilis (74)
Ampicillin/sulbactam 2 32 0.5 to 32 78.4/10.8 78.4/21.6
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Table 3 (Continued)
Organism (no. tested)/antimicrobial agent MIC (mg/L) CLSIa %S/%R EUCASTa %S/%R
50% 90% Range
Cefoperazone 1 >32 ≤0.25 to >32 74.3/20.3 −/−
Cefoperazone/sulbactamb 1 4 ≤0.25 to 16 100.0/0.0 −/−
Piperacillin/tazobactam ≤0.5 1 ≤0.5 to 2 100.0/0.0 100.0/0.0
Tigecyclinec 2 4 0.5 to >4 85.1/1.4 32.4/14.9
Amikacin 4 8 1 to >32 95.9/2.7 90.5/4.1
Amoxicillin/clavulanate ≤1 8 ≤1 to >8 93.2/6.8 93.2/6.8
Ampicillin 2 >8 0.5 to >8 52.7/47.3 52.7/47.3
Cefepime ≤0.5 >16 ≤0.5 to 16 81.1/17.6 75.7/20.3
Ceftazidime 0.06 2 0.03 to >32 94.6/5.4 87.8/5.4
Ceftriaxone ≤0.06 >8 ≤0.06 to >8 75.7/23.0 75.7/23.0
Gentamicin ≤1 >8 ≤1 to >8 78.4/21.6 75.7/21.6
Imipenem 1 2 ≤0.12 to 4 73.0/4.1 95.9/0.0
Levoﬂoxacin ≤0.12 >4 ≤0.12 to >4 73.0/23.0 67.6/27.0
Meropenem ≤0.06 ≤0.06 ≤0.06 to 0.12 100.0/0.0 100.0/0.0
Tobramycin 1 16 0.5 to 16 77.0/12.2 73.0/23.0
Trimethoprim/sulfamethoxazole >4 >4 ≤0.5 to >4 47.3/52.7 47.3/51.4
Enterobacter spp. (272)e
Cefoperazone 2 >32 ≤0.25 to >32 59.9/34.9 −/−
Cefoperazone/sulbactamb 1 32 ≤0.25 to >32 84.9/6.3 −/−
Piperacillin/tazobactam 4 >64 ≤0.5 to >64 75.7/10.7 69.5/24.3
Tigecyclinec 0.25 1 0.06 to 4 97.8/0.0 94.1/2.2
Amikacin 2 16 0.5 to >32 94.1/4.0 86.8/5.9
Cefepime ≤0.5 >16 ≤0.5 to >16 84.6/12.1 70.2/21.0
Ceftazidime 0.5 >32 0.06 to >32 63.2/33.5 57.7/36.8
Ceftriaxone 0.5 >8 ≤0.06 to >8 55.5/44.5 55.5/44.5
Gentamicin ≤1 >8 ≤1 to >8 77.9/19.5 76.5/22.1
Levoﬂoxacin ≤0.12 >4 ≤0.12 to >4 80.9/16.5 79.4/19.1
Meropenem ≤0.06 0.12 ≤0.06 to >8 98.2/1.5 98.5/0.4
Tetracycline 2 >8 0.5 to >8 74.3/19.1 −/−
Tobramycin 0.5 >16 ≤0.12 to >16 69.9/28.3 69.5/30.1
Trimethoprim/sulfamethoxazole ≤0.5 >4 ≤0.5 to >4 71.0/29.0 71.0/28.3
Indole-positive Proteus spp. (94)f
Cefoperazone 4 >32 ≤0.25 to >32 71.3/21.3 −/−
Cefoperazone/sulbactamb 2 8 ≤0.25 to 32 98.9/0.0 −/−
Piperacillin/tazobactam ≤0.5 4 ≤0.5 to >64 98.9/1.1 97.9/1.1
Tigecyclinec 0.5 2 0.25 to 4 94.7/0.0 89.4/5.3
Amikacin 2 8 0.5 to >32 94.7/4.3 92.6/5.3
Cefepime ≤0.5 16 ≤0.5 to >16 89.4/4.3 80.9/13.8
Ceftazidime 0.25 16 0.03 to >32 80.9/13.8 70.2/19.1
Ceftriaxone 0.12 >8 ≤0.06 to >8 68.1/25.5 68.1/25.5
Gentamicin ≤1 >8 ≤1 to >8 68.1/27.7 61.7/31.9
Imipenem 2 2 0.25 to 4 35.1/6.4 93.6/0.0
Levoﬂoxacin 1 >4 ≤0.12 to >4 62.8/25.5 55.3/37.2
Meropenem ≤0.06 0.12 ≤0.06 to 1 100.0/0.0 100.0/0.0
Tobramycin 1 16 0.25 to >16 73.4/14.9 68.1/26.6
Trimethoprim/sulfamethoxazole >4 >4 ≤0.5 to >4 43.6/56.4 43.6/56.4
Serratia spp. (142)g
Cefoperazone 2 >32 0.5 to >32 78.9/14.1 −/−
Cefoperazone/sulbactamb 2 16 0.5 to >32 90.8/4.9 −/−
Piperacillin/tazobactam 2 32 ≤0.5 to >64 89.4/7.0 85.9/10.6
Tigecyclinec 0.5 1 0.25 to >4 95.8/0.7 90.1/4.2
Amikacin 2 16 0.5 to >32 90.8/5.6 85.9/9.2
Cefepime ≤0.5 4 ≤0.5 to >16 92.3/7.0 84.5/9.2
Ceftazidime 0.12 16 0.06 to >32 84.5/13.4 81.0/15.5
Ceftriaxone 0.25 >8 ≤0.06 to >8 75.4/23.2 75.4/23.2
Gentamicin ≤1 >8 ≤1 to >8 85.2/13.4 83.1/14.8
Levoﬂoxacin ≤0.12 4 ≤0.12 to >4 88.7/7.7 83.1/11.3
Meropenem ≤0.06 0.12 ≤0.06 to 4 98.6/0.7 99.3/0.0
Tobramycin 4 >16 0.25 to >16 73.9/19.7 45.8/26.1
Trimethoprim/sulfamethoxazole ≤0.5 >4 ≤0.5 to >4 84.5/15.5 84.5/12.7
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Table 3 (Continued)
Organism (no. tested)/antimicrobial agent MIC (mg/L) CLSIa %S/%R EUCASTa %S/%R
50% 90% Range
Citrobacter spp. (56)h
Cefoperazone 1 >32 ≤0.25 to >32 69.6/25.0 −/−
Cefoperazone/sulbactamb 0.5 16 ≤0.25 to >32 91.1/7.1 −/−
Piperacillin/tazobactam 4 64 1 to >64 80.4/5.4 76.8/19.6
Tigecyclinec 0.25 0.5 0.06 to 2 100.0/0.0 96.4/0.0
Amikacin 2 32 0.5 to >32 89.3/5.4 83.9/10.7
Cefepime ≤0.5 16 ≤0.5 to 16 87.5/10.7 76.8/16.1
Ceftazidime 0.5 >32 0.06 to >32 71.4/25.0 66.1/28.6
Ceftriaxone 0.25 >8 ≤0.06 to >8 66.1/32.1 66.1/32.1
Gentamicin ≤1 4 ≤1 to >8 91.1/8.9 83.9/8.9
Levoﬂoxacin ≤0.12 1 ≤0.12 to >4 92.9/5.4 92.9/7.1
Meropenem ≤0.06 ≤0.06 ≤0.06 to 4 98.2/1.8 98.2/0.0
Tetracycline 1 4 1 to >8 91.1/8.9 −/−
Tobramycin 1 16 0.25 to 16 80.4/19.6 78.6/19.6
Trimethoprim/sulfamethoxazole ≤0.5 >4 ≤0.5 to >4 76.8/23.2 76.8/23.2
H. inﬂuenzae (128)
Piperacillin/tazobactam ≤0.5 ≤0.5 ≤0.5 100.0/0.0 −/−
Tigecyclinec 0.25 0.5 0.06 to 1 86.7/- −/−
Amoxicillin/clavulanate ≤1 2 ≤1 to 2 100.0/0.0 100.0/0.0
Ampicillin 0.25 >8 ≤0.12 to >8 70.3/28.9 70.3/29.7
Cefepime ≤0.5 ≤0.5 ≤0.5 100.0/− 100.0/0.0
Ceftriaxone ≤0.06 ≤0.06 ≤0.06 to 0.5 100.0/− 99.2/0.8
Levoﬂoxacin ≤0.12 ≤0.12 ≤0.12 100.0/− 100.0/0.0
Meropenem ≤0.06 0.12 ≤0.06 to 0.25 100.0/− 100.0/0.0
Tetracycline 0.5 0.5 ≤0.12 to 16 98.4/1.6 98.4/1.6
Trimethoprim/sulfamethoxazole ≤0.5 >4 ≤0.5 to >4 61.7/35.2 61.7/37.5
M. catarrhalis (33)
Tigecyclinec 0.06 0.06 0.03 to 0.06 −/− −/−
Amoxicillin/clavulanate ≤1 ≤1 ≤1 100.0/0.0 100.0/0.0
Cefepime 1 2 ≤0.5 to 4 −/− 100.0/0.0
Ceftriaxone 0.25 0.5 ≤0.06 to 0.5 100.0/− 100.0/0.0
Levoﬂoxacin ≤0.12 ≤0.12 ≤0.12 to 1 100.0/− 100.0/0.0
Meropenem ≤0.06 ≤0.06 ≤0.06 −/− 100.0/0.0
Tetracycline 0.25 0.25 ≤0.12 to 0.5 100.0/0.0 100.0/0.0
Trimethoprim/sulfamethoxazole ≤0.5 ≤0.5 ≤0.5 100.0/0.0 100.0/0.0
P. aeruginosa (586)
Cefoperazoneb 32 >32 0.5 to >32 49.3/39.4 −/−
Cefoperazone/sulbactam 16 >32 0.5 to >32 55.8/25.4 −/−
Piperacillin/tazobactam 16 >64 ≤0.5 to >64 58.5/22.9 58.5/41.5
Amikacin 4 >32 ≤0.25 to >32 75.4/20.5 71.3/24.6
Cefepime 8 16 ≤0.5 to 16 63.8/25.9 63.8/36.2
Ceftazidime 4 >32 0.25 to >32 65.7/29.4 65.7/34.3
Colistin 1 2 ≤0.25 to 4 99.5/0.0 99.5/0.5
Gentamicin 2 >8 ≤1 to >8 67.4/29.4 67.4/32.6
Imipenem 2 >8 ≤0.12 to >8 52.9/44.9 55.1/28.5
Levoﬂoxacin 2 >4 ≤0.12 to >4 56.8/38.2 47.8/43.2
Meropenem 2 >8 ≤0.06 to >8 54.4/38.4 54.4/28.2
Tobramycin 0.5 16 ≤0.12 to 16 70.1/29.0 70.1/29.9
Acinetobacter spp. (494)i
Cefoperazone/sulbactam 16 32 ≤0.25 to >32 59.3/8.1 −/−
Tigecycline 1 4 ≤0.03 to >4 −/− −/−
Amikacin >32 >32 0.5 to >32 25.3/67.6 23.1/74.7
Colistin 0.5 2 ≤0.25 to >4 98.0/2.0 98.0/2.0
Doxycycline 1 >8 ≤0.06 to >8 80.4/18.6 −/−
Gentamicin >8 >8 ≤1 to >8 29.2/58.9 29.2/70.9
Imipenem >8 >8 ≤0.12 to >8 22.9/75.7 22.5/75.7
Meropenem >8 >8 ≤0.06 to >8 23.1/75.5 21.9/75.5
Tetracycline 8 >8 0.5 to >8 27.3/43.3 −/−
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Table 3 (Continued)
Organism (no. tested)/antimicrobial agent MIC (mg/L) CLSIa %S/%R EUCASTa %S/%R
50% 90% Range
Tobramycin 16 16 0.25 to 16 47.8/51.6 47.8/52.2
Trimethoprim/sulfamethoxazole >4 >4 ≤0.5 to >4 22.1/77.9 22.1/75.3
a Criteria as published by the CLSI and EUCAST.9,10
b Criteria as published by the CLSI for cefoperazone used for cefoperazone/sulbactam.9
c USA-FDA breakpoints were applied when available.11
d Includes: Klebsiella oxytoca (51 strains), K. ozaenae (two strains), K. pneumoniae (460 strains), and unspeciated Klebsiella (four strains).
e Includes: Enterobacter aerogenes (47 strains), E. cloacae (202 strains), E. gergoviae (two strains), and unspeciated Enterobacter (21 strains).
f Includes: Morganella morganii (72 strains), Proteus vulgaris (12 strains), P. rettgeri (ﬁve strains), P. stuartii (four strains), and unspeciated Providencia
(one strain).
g Includes: Serratia liquefaciens (one strain), S. marcescens (131 strains), and unspeciated Serratia (10 strains).
s), C.
 stra
 listedh Includes: Citrobacter amalonaticus (two strains), C. braakii (two strain
i Includes: Acinetobacter baumannii (468 strains), A. haemolyticus (two
Acinetobacter (nine strains); only drugs with >20% susceptibility are
at 24.3% and several UTI-targeted antimicrobials (ampicillin
and  TMP/SMX) were only 47.3–52.7% effective in vitro.
Among other enteric bacilli, Enterobacter spp. showed a CRE
rate  at 2.9% with higher rates in Colombia and Venezuela
(10.0–12.5%). Amikacin, cefoperazone/sulbactam, cefepime,
carbapenems and tigecycline were quite active against these
species,  as were nearly all tested agents versus H. inﬂuenzae
(128)  and M.  catarrhalis (33); see Table 3.
Table 4 – Activity of 12 antimicrobial agents when tested again
isolated in Latin American medical centers (511 strains culture
Organism (no. tested)/antimicrobial agent MIC
50% 90%
E. coli (240)
Cefoperazone/sulbactamb 8 32 
Piperacillin/tazobactam 8 64 
Tigecyclinec 0.12 0.25 
Amikacin 8 16 
Cefepime 16 16 
Colistin 0.5 0.5 
Gentamicin >8 >8 
Levoﬂoxacin >4 >4 
Meropenem ≤0.06 ≤0.06
Tetracycline >8 >8 
Tobramycin 16 16 
Trimethoprim/sulfamethoxazole >4 >4 
Klebsiella spp. (271)d
Cefoperazone/sulbactamb 32 >32 
Piperacillin/tazobactam 64 >64 
Tigecyclinec 0.25 1 
Amikacin 4 >32 
Cefepime 16 16 
Colistin 0.5 1 
Gentamicin >8 >8 
Levoﬂoxacin >4 >4 
Meropenem ≤0.06 >8 
Tetracycline 8 >8 
Tobramycin 16 16 
Trimethoprim/sulfamethoxazole >4 >4 
a Criteria as published by the CLSI and EUCAST.9,10
b Criteria as published by the CLSI for cefoperazone used for cefoperazon
c USA-FDA breakpoints were applied when available.11
d Includes: Klebsiella oxytoca (16 strains), K. ozaenae (one strain), K. pneumon freundii (39 strains), C. koseri (12 strains), and C. sedlakii (one strain).
ins), A. lwofﬁi (11 strains), A. ursingii (four strains), and unspeciated
, this includes ampicillin/sulbactam.
P. aeruginosa (586) were most susceptible to amikacin
(75.4%), tobramycin (70.1%) and colistin (99.5%; Table 3). Car-
bapenem  resistance was  high due to endemic -lactamase
(SPM-1, usually in Brazil), but the most elevated rates were
noted  in Guatemala (75.8%), Peru (62.5–68.8%) and Ecuador
(55.6%). The most active -lactam was ceftazidime (65.7%,
MIC50 at 4 mg/L). Acinetobacter spp. (494, four species) were
signiﬁcantly inhibited (% susceptible) only by colistin (98.6%),
st ESBL-phenotype Escherichia coli and Klebsiella spp.
d in 2011).
 (mg/L) CLSIa %S/%R EUCASTa %S/%R
 Range
≤0.25 to >32 81.3/6.3 −/−
≤0.5 to >64 72.5/8.3 52.9/27.5
0.06 to 1 100.0/0.0 100.0/0.0
1 to >32 93.8/2.1 82.1/6.3
≤0.5 to 16 25.8/64.2 8.8/81.3
≤0.25 to 2 −/− 100.0/0.0
≤1 to >8 46.3/52.9 43.8/53.8
≤0.12 to >4 16.3/81.3 16.3/83.8
 ≤0.06 to 0.5 100.0/0.0 100.0/0.0
≤0.25 to >8 20.8/79.2 −/−
0.5 to 16 22.5/71.7 20.8/77.5
≤0.5 to >4 24.2/75.8 24.2/74.2
≤0.25 to >32 46.5/41.0 −/−
1 to >64 38.0/46.9 25.8/62.0
≤0.03 to 4 97.0/0.0 92.3/3.0
0.5 to >32 79.7/11.4 67.9/20.3
≤0.5 to 16 28.0/62.7 8.1/80.8
≤0.25 to >4 −/− 93.4/6.6
≤1 to >8 42.8/50.6 40.2/57.2
≤0.12 to >4 43.9/54.2 41.3/56.1
≤0.06 to >8 81.6/15.1 84.9/10.7
≤0.25 to >8 46.5/49.1 −/−
≤0.12 to 16 21.8/69.0 20.7/78.2
≤0.5 to >4 31.0/69.0 31.0/66.1
e/sulbactam.9
iae (252 strains), and unspeciated Klebsiella (two strains).
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efoperazone/sulbactam (59.3%), doxycycline (80.4%) and tige-
ycline  (MIC90, 4 mg/L). All carbapenems, aminoglycosides
nd ampicillin/sulbactam showed susceptibility rates at <50%,
any <20%; see Table 3.
Monitoring of nearly 5000 LATAM pathogens in 2011 docu-
ents  increasing antimicrobial resistances among nearly all
ampled  species (Tables 1–3), conﬁrming earlier reports.1,3,6
lthough methicillin resistance was  elevated among staphylo-
occi  (47.8–83.9%), several agents (daptomycin, glycopeptides,
inezolid and tigecycline) retained potent activity in LATAM
ike  elsewhere in the world.4–7 VRE appears to be expand-
ng  (14.2–15.1%, in 10 nations) as are non-susceptible rates
or  -lactams in S. pneumoniae. In contrast, USA rates of VRE
articularly among bacteremia isolates of E. faecium have esca-
ated  to more  than 80%,12 and ceftriaxone non-susceptible
ates were  at 12.5% in 2009 samples of pneumococci.13 Rare
inezolid-resistant (<1.0% overall) CoNS and enterococci were
oted  with cfr and target site mutations, as previously noted
n  Mexico.6
-Lactamase-mediated (ESBL, MBL  [NDM-1], Class A and
 carbapenamases) resistance in E. coli, Klebsiella spp., some
ther  Enterobacteriaceae, and non-fermentative bacilli con-
inues  to evolve (Table 3) to levels of 37.3–52.4% and few drugs
ave  ≥90.0% level inhibition at published breakpoints.1–4,14
his demands routine use of combination empiric therapies
irected  by surveillance programs  and patient isolate tests for
ATAM patients; and interventions will be required to control
urther  resistance escalation in this geographic region.
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